Bevacizumab is a recombinant humanized monoclonal antibody (IgG1) that revolutionized cancer therapy as the first clinically approved angiogenesis inhibitor. It specifically targets and neutralizes vascular endothelial growth factor A (VEGF-A), a key signaling protein that stimulates the formation of new blood vessels (angiogenesis). By binding to VEGF-A, bevacizumab blocks its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on endothelial cells, thereby inhibiting tumor blood vessel growth. This “starves” the tumor of oxygen and nutrients, suppresses metastasis, and normalizes existing abnormal tumor vasculature to improve drug delivery. It is approved for the treatment of various metastatic cancers, including colorectal, lung, ovarian, cervical, and renal cell cancers, as well as glioblastoma, and is used in combination with chemotherapy or as maintenance therapy.